Mihael MD - Vanda Pharmaceuticals President, Founder
| VNDA Stock | USD 4.94 0.05 1.00% |
Insider
Mihael MD is President, Founder of Vanda Pharmaceuticals
| Age | 65 |
| Phone | 202 734 3400 |
| Web | https://www.vandapharma.com |
Vanda Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0364) % which means that it has lost $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0302) %, meaning that it created substantial loss on money invested by shareholders. Vanda Pharmaceuticals' management efficiency ratios could be used to measure how well Vanda Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Cullinan Oncology LLC | 51 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Timothy Moore | Instil Bio | 63 | |
| Nicole Lambert | Arcus Biosciences | 46 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Mirella Toro | Annexon | N/A | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Arnon Rosenthal | Annexon | 68 | |
| David Socks | Phathom Pharmaceuticals | 50 | |
| Ying Huang | Legend Biotech Corp | 52 | |
| Michelle Doig | Nuvation Bio | 46 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Steven Shamah | 2Seventy Bio | N/A | |
| MBA MBA | Biomarin Pharmaceutical | 71 | |
| Dr MBA | Blueprint Medicines Corp | 55 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Alexis AM | Blueprint Medicines Corp | 53 | |
| Jason Barker | Arcus Biosciences | 49 | |
| Celia ReyesHoke | Liquidia Technologies | N/A | |
| Kathleen Wilkinson | 2Seventy Bio | 52 | |
Management Performance
| Return On Equity | -0.0302 | ||||
| Return On Asset | -0.0364 |
Vanda Pharmaceuticals Leadership Team
Elected by the shareholders, the Vanda Pharmaceuticals' board of directors comprises two types of representatives: Vanda Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vanda. The board's role is to monitor Vanda Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vanda Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vanda Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Howell, Chief Officer | ||
| Mihael MD, President, Founder | ||
| Kevin Moran, CFO VP | ||
| Elizabeth Every, Head Affairs | ||
| Joakim Wijkstrom, Chief Marketing Officer | ||
| Timothy Williams, Senior Vice President General Counsel, Secretary | ||
| Gunther Birznieks, Senior Vice President - Business Development | ||
| Timothy JD, General VP |
Vanda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vanda Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0302 | ||||
| Return On Asset | -0.0364 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | (66.33 M) | ||||
| Shares Outstanding | 58.31 M | ||||
| Shares Owned By Insiders | 3.15 % | ||||
| Shares Owned By Institutions | 76.98 % | ||||
| Number Of Shares Shorted | 3.72 M | ||||
| Price To Earning | 24.83 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vanda Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.